VolitionRx Encounters NYSE American Compliance Notice
VolitionRx Limited (NYSE AMERICAN: VNRX) has recently made headlines as it received a compliance notice from the NYSE American. This pivotal moment for the company, a key player in the epigenetics sector, was communicated on February 6, 2026, detailing its non-compliance with certain financial standards that are vital for maintaining its listing on the NYSE American.
Understanding the Compliance Notification
The notification specifies that VolitionRx has not met the equity requirements stipulated within the NYSE American Company Guide. Specifically, these requirements include maintaining stockholders' equity of at least $2 million if there have been losses in two of the last three fiscal years, at least $4 million if losing in three of the last four years, and $6 million if losses persist over five years. The company is also ineligible for any exemptions that might otherwise facilitate its compliance.
The Required Plan for Compliance
To address this situation, VolitionRx is required to submit a comprehensive plan detailing its approach to regain compliance. This plan must be presented to the NYSE American by March 8, 2026, outlining the actions the company will undertake to ensure it meets the necessary standards by August 6, 2027. Acceptance of this plan is critical; failure to comply can lead to delisting consequences from the exchange.
Current Status of VolitionRx's Shares
Despite the notice, there is no immediate threat to VolitionRx's stock trading status on the NYSE American. Shares will continue to be traded under the symbol "VNRX"; however, they will reflect an additional designation of ".BC" to indicate they are below compliance. This identifier is crucial for investors who are keeping track of the company's standing in relation to the exchange's ongoing requirements.
Commitment to Compliance
VolitionRx is steadfast in its commitment to restoring compliance with the NYSE American's standards. The company emphasizes its intent to devise a strategic plan that aligns with regulatory expectations. While the leadership is confident in their proposed actions, there remains an element of uncertainty regarding their ability to achieve compliance within the stipulated time.
About VolitionRx Limited
VolitionRx is dedicated to advancing the field of epigenetics, firmly focused on developing innovative solutions for early disease detection. Their mission extends beyond human health to improving life quality for animals facing serious health challenges.
Through its specialized subsidiaries, VolitionRx is creating straightforward, cost-effective blood tests aimed at detecting and monitoring various diseases, including specific cancers and other conditions linked to NETosis, such as sepsis. Their ultimate goal is to enhance patient outcomes through timely diagnosis and continuous monitoring.
Research and Development Efforts
Research and development are at the core of VolitionRx's operations, with key centers in Belgium complemented by innovation efforts in the United States and the United Kingdom. These locations are vital for cultivating groundbreaking discoveries that elevate the standards of medical testing and protocols.
Frequently Asked Questions
What does the compliance notice from NYSE American entail?
The compliance notice indicates that VolitionRx has not met required equity standards and must submit a plan to regain compliance.
When is VolitionRx required to submit its compliance plan?
The company must submit its plan by March 8, 2026.
Will VolitionRx's stock continue to trade on NYSE American?
Yes, despite the notice, VolitionRx's stock will continue to trade, although it will receive a designation indicating it is below compliance.
What is the ultimate goal of VolitionRx regarding compliance?
The company's goal is to regain compliance with the NYSE American standards by August 6, 2027.
What is the focus of VolitionRx's research and development?
VolitionRx focuses on developing blood tests for early disease detection and monitoring for humans and animals.